RUXOPEG is the first study to formally assess the safety and efficacy of Rux + IFNa combination in MF patients never exposed to either drugs before
First in ASH 2018 Series
by David Wallace
Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018. Discussing Ruxopeg Phase 1-2 Trial of Ruxolitinib and Pegasys combo therapy in Patients with Myelofibrosis.
Sponsored by Incyte Corporation